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Abstract
Background: Reduced lung function predicts increased mortality, but its prevalence may vary depending on
definition considered, use of bronchodilation and applied reference values. We aimed to assess lung function
abnormalities in Lausanne, Switzerland, and their association with clinical history.
Methods: In a general population sample, spirometry was performed and bronchodilation applied if the ratio
forced expiratory volume in 1 s (FEV1) / forced vital capacity (FVC) or the FVC was below the lower limit of normal
(LLN) according to Global Lung Function Initiative 2012 references. Results for FEV1/FVC according to the LLN were
compared to the 0.7 fixed ratio. Respiratory risk factors, symptoms and self-reported respiratory diagnoses were
recorded through a questionnaire.
Results: Out of the 3342 included subjects, 3.8% had chronic obstruction and 2.5% reversible obstruction when
using the LLN; possible lung restriction alone was present in 1.8%, and associated with chronic obstruction in 0.4%.
Ever smokers had a higher prevalence of abnormal spirometry, chronic obstruction and reversible obstruction; there
was no difference with regard to possible restriction. Overall, chronic airway obstruction was found in 8.9% of
current smokers, 4.6% of former smokers and 1.5% of never smokers. Only one third of participants with chronic
obstruction were aware of a respiratory disease.
Conclusion: Prevalence of abnormal lung function in the population of Lausanne is low. This may be due to a low rate
of ever-smokers, the application of a full bronchodilation dose, but also to inherent characteristics of this population.
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Introduction
A reduced lung function, as expressed by the forced expira-
tory volume in one second (FEV1) and the forced vital
capacity (FVC), has been shown to be a marker of prema-
ture death, mainly through cardiopulmonary complications
[1, 2]. The definition of abnormal spirometry results has
however been subject to debate, especially the use of a fixed
FEV1/FVC ratio versus a lower limit of normal (LLN) to
diagnose airway obstruction [3, 4]. Furthermore, the use of
bronchodilation is not uniform across studies. Finally,
different reference values have been used, the European
Community of Coal and Steel (ECCS) reference equations.
[5], the American National Health and Nutrition Examin-
ation Survey (NHANES) III reference values [6], and even-
tually the more recent and comprehensive Global Lung
Function Initiative (GLI) 2012 reference equations. [7].
Given the variety of methods and reference equations
cited above, the currently available data on prevalence of
abnormal lung function in general populations are diffi-
cult to compare.
The primary objective of the PneumoLaus study was to
assess the prevalence of lung function abnormalities in the
population of the city of Lausanne, Switzerland, according
to GLI 2012 reference values [7], using bronchodilation in
case of airway obstruction. The secondary objectives of
our study were to assess in the same population if a higher
prevalence of lung function abnormalities was associated* Correspondence: Alexandra.Lenoir@chuv.ch1Department of Medicine, Respiratory Medicine, Lausanne University Hospital
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with risk factors for respiratory diseases, respiratory symp-
toms or self-reported history of respiratory diagnoses.
Methods
Setting and selection of participants
The PneumoLaus study is a part of the CoLaus/PsyCo-
Laus study, a population-based, prospective study investi-
gating the prevalence and determinants of cardiovascular
disease in the city of Lausanne, Switzerland. The sampling
procedure of the CoLaus/PsyCoLaus study has been
described previously [8]. In brief, all subjects aged 35–75
years living in the city of Lausanne were eligible, and a
simple, non-stratified random sample of 6733 participants
was obtained using the population register of the city and
examined between June 2003 and May 2006. The first
follow-up was conducted between April 2009 and
September 2012, and the second follow-up was conducted
between May 2014 and April 2017.
Starting in June 2014, all participants were invited to
take part in the PneumoLaus study. Examinations were
conducted between June 2014 and August 2017. All
ethnic groups were included.
Spirometry
Lung function was assessed using a MasterScreen-PFT
spirometer (Carefusion, Hoechberg, Germany), with
Sentry Suite software (Version 2.17). All spirometries
were performed by one single trained, very experienced
respiratory lab technician.
Spirometry was performed in a sitting position. A nose
clip was used to prevent air leaks. Testing for a partici-
pant was performed until: 1) the participant was able to
achieve a reproducible spirometry result; 2) a maximum
of eight attempts had been obtained; or 3) the partici-
pant could not continue. Each manoeuvre was automat-
ically assessed by computer, based upon acceptability
and reproducibility criteria according to the American
Thoracic Society (ATS) – European Respiratory Society
(ERS) standards [9]. These criteria were used as a refer-
ence aid to ensure a good quality of spirometry during
testing.
Reference values were applied according to GLI 2012
adjusting for the following ethnic origins: Caucasian,
African, north-east Asian, south-east Asian and other
[7]. If FEV1/FVC or FVC was found to be below the
LLN, spirometry was repeated 10–15min after adminis-
tration of 4 × 100 μg of salbutamol via a metered-dose
inhaler and a spacer.
Normal spirometry was defined by baseline FEV1/FVC
ratio and FVC above LLN, representing the lower 5th
percentile based on age, gender, height and ethnicity
[10]. Chronic airway obstruction was defined as FEV1/
FVC below LLN after bronchodilation (BD). Reversible
airway obstruction was defined as FEV1/FVC below
LLN before BD and above LLN after BD. In case FVC
was below LLN before BD and normalised after BD, we
suspected air trapping and also classified these subjects
as reversible airway obstruction. Possible lung restriction
was defined as FVC below LLN after BD [10]. Finally,
the prevalence of airway obstruction was also assessed
when defined by an FEV1/FVC ratio < 0.70.
Respiratory risk factors, symptoms and history of
respiratory diagnoses
Information on respiratory status was obtained by a
face-to-face structured interview by the respiratory tech-
nician on the day of spirometry.
Smoking was categorised as current, former or never.
Number of pack-years was defined as the number of
cigarettes smoked per day divided by 20 multiplied by the
number of years that the participant smoked. Exposure to
second-hand tobacco smoke in childhood and in adult-
hood, as well as exposure to other fumes or smokes, was
also assessed.
Respiratory symptoms such as cough, sputum produc-
tion and shortness of breath according to the Modified
Medical Research Council (mMRC) dyspnoea scale [11]
were documented.
Self-reported history of the following was also noted: a
medical diagnosis of asthma; chronic obstructive pulmon-
ary disease (COPD), emphysema or chronic bronchitis;
other respiratory diseases; or previous lung operations.
Other covariates
Body weight and height were measured with participants
standing without shoes in light indoor clothing. Weight
was measured in kilograms to the nearest 0.1 kg using a
Seca™ scale (Seca, Hamburg, Germany). Height was
measured to the nearest 5 mm using a Seca™ height
gauge (Seca, Hamburg, Germany). Body mass index
(BMI) was defined as weight/height2 in kg/m2.
Inclusion criteria for spirometry
Manoeuvres were judged by the lab technician and one
of two authors (JF, AL) from the flow-volume curve
display. Spirometries were included in the analysis if the
following conditions were fulfilled: no artefacts, no
abrupt termination, no glottis closure or cough, no leaks,
no large back extrapolated volume, as well as a maximal
continuous effort [12].
Statistical methods
Statistical analysis was performed using Stata™ version
15.0 software (StataCorp, College Station, TX, USA).
Participants’ characteristics were expressed as number
(percentage) for categorical variables, and as average
± standard deviation or median [interquartile range]
for continuous variables. Between-group comparisons
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were performed using chi-square or Fisher’s exact test for
categorical variables, and student’s t-test, analysis of vari-
ance or Kruskal-Wallis nonparametric test for continuous
variables. For categories of spirometry, post-hoc between-
group comparisons of continuous variables were per-
formed using Scheffe’s method; normal spirometry was
considered as the reference. Multivariable analysis was
conducted using multinomial (polytomous) logistic
regression, with spirometry categories as the dependent
variable and all covariates significantly associated in the
bivariate analysis as independent variables. Normal
spirometry was considered as the reference, and results
were expressed as relative risk ratio and (95% confidence
interval). Statistical significance was considered for a
two-sided test with p < 0.05.
Results
Participant selection and clinical characteristics
Of the initial 4882 eligible subjects, 3353 (68.7%) agreed
to take part in the PneumoLaus study, and 3342 (68.5%)
were included in the analysis. The selection procedure is
summarized in Fig. 1. Baseline characteristics of the
included participants as well as their gender distribution
are shown in Table 1. There was a slight female prepon-
derance; the vast majority of participants were Cauca-
sian; mean BMI was ~ 26 kg/m2.
Overall spirometry results
In our sample, 91.9% participants had a normal spirom-
etry. Airway obstruction was found in 6.3%: reversible in
2.5% and chronic in 3.8%. Possible lung restriction alone
was present in 1.8%, and associated with chronic
obstruction in 0.4%. There was only one case of revers-
ible obstruction with possible restriction. Of all chronic
airway obstructions, 58.6% could be classified as mild,
20.3% as moderate, 13.3% as moderately severe, 6.2% as
severe and 1.6% as very severe [10]. When defined by
FEV1/FVC < 0.70, airway obstruction was present in
12.3% of subjects. Among subjects with airway obstruc-
tion according to this fixed ratio but not according to
the LLN (n = 224), 8.0% had a maximal mid-expiratory
flow (MMEF25–75) below the LLN. This was higher
than the prevalence of low MMEF25–75 in subjects with
normal FEV1/FVC according to both definitions and
lower than the prevalence of low MMEF25–75 in
subjects with FEV1/FVC < LLN.
Spirometry results by gender are shown in Fig. 2.
Women were more likely to have normal spirometry
(93.1% vs. 90.3%, p = 0.004), and had lower rates of
possible lung restriction (1.6% vs. 3.0%, p = 0.005) and
chronic obstruction (3.1% vs. 4.7%, p = 0.025). Relative
risk ratio (RRR) for chronic obstruction in men
compared to women was 1.59 (p = 0.02) according to
multivariate analysis adjusting for all other variables;
RRR for possible lung restriction in men was 1.80
compared to women (p = 0.037). Gender differences in
spirometric categories persisted if applied to never-
smokers only, with lower prevalence of possible lung
restriction (1.7% vs. 4.0%, p = 0.003) and chronic
obstruction (1.0% vs. 2.3%, p = 0.029) in female
never-smokers. This difference disappeared when
applied to ever-smokers only. There was no gender
difference for reversible obstruction.
Average age did not differ significantly between
spirometric result categories.
Risk factors for respiratory diseases and their association
with lung function abnormalities
Questionnaire results for respiratory risk factors
according to spirometric categories are shown in
Table 2. Former and current smokers constituted half
of participants; they had a higher prevalence of
Fig. 1 Selection procedure for the participants of the PneumoLaus
study, 2014-2017, Lausanne, Switzerland
Table 1 Baseline characteristics of the participants of the
PneumoLaus study, 2014–2017, Lausanne, Switzerland
Characteristics Overall Women Men p-value
Sample size 3342 1863 1479
Age (years) 62.6 ± 10.0 63.2 ± 9.9 62.0 ± 10.0 < 0.001
Caucasian (%) 3261 (97.6) 1822 (97.8) 1439 (97.3) 0.347
Body mass
index (kg/m2)
26.4 ± 4.7 25.8 ± 5.0 27.0 ± 4.0 < 0.001
Results are expressed as number of participants and (column percentage) for
categorical variables and as average ± standard deviation for continuous
variables. Between-group analysis performed using chi-square test for
categorical variables and student’s t-test for continuous variables
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abnormal spirometry (11.0% vs. 5.3%, p < 0.001),
chronic obstruction (6.1% vs. 1.5%, p < 0.001) and
reversible obstruction (3.5% vs. 1.4%, p < 0.001). There
was no difference with regard to possible lung restric-
tion in bivariate analysis (p = 0.183), and multivariate
analysis suggested a protective effect of smoking for
possible restriction. Overall, chronic airway obstruction
was found in 8.9% of current smokers, 4.6% of former
smokers and 1.5% of never smokers (p < 0.001). Among
ever smokers, mean tobacco consumption was highest
in the chronic obstruction category. Women were more
often never-smokers (54.5% vs. 43.7%) and had less
pack years if they were ever-smokers (21.5 vs. 27.5 pack
years, p < 0.001).
Mean FEV1 as percentage of predicted was lower in
ever-smokers compared to never-smokers (98.3% vs.
102.8%, p < 0.001) as were FVC (101.0% vs. 102.5%,
p = 0.003) and the FEV1/FVC ratio (75.6% vs. 78.3%,
p < 0.001).
Almost half of participants had been exposed to
second-hand tobacco smoke in childhood, slightly more
than half in adulthood, with no gender difference. In
Fig. 2 Spirometry results according to gender (M, male; F, female), Pneumolaus study, 2014-2017, Lausanne, Switzerland
Table 2 Respiratory risk factors according to spirometry results. PneumoLaus study, 2014–2017, Lausanne, Switzerland
Question Overall Normal spirometry Chronic obstruction Reversible obstruction Possible restriction p-value
N 3342 3070 128 83 61
Smoking status: < 0.001
Never 1662 (49.7) 1574 (51.3) 25 (19.5) 24 (28.9) 39 (63.9)
Former 1075 (32.2) 975 (31.8) 49 (38.3) 37 (44.6) 14 (23.0)
Current 605 (18.1) 521 (17.0) 54 (42.2) 22 (26.5) 8 (13.1)
Ever smoker (%) 1680 (50.3) 1496 (48.7) 103 (80.5) 59 (71.1) 22 (36.1) < 0.001
Mean pack years §ǂ 20 [10–30] 19 [10–30] 33 [15–48] 20 [15–35] 25 [10–40] < 0.001
Second-hand tobacco:
Before age 18 1402 (42.0) 1295 (42.2) 54 (42.2) 26 (31.3) 27 (44.3) 0.253
As an adult 1707 (51.1) 1547 (50.4) 88 (68.8) 48 (57.8) 24 (39.3) < 0.001
Other smoke / fumes 554 (16.6) 499 (16.3) 25 (19.5) 13 (15.7) 17 (27.9) 0.082
BMI (kg/m2) 26.4 ± 4.7 26.3 ± 4.6 a 25.3 ± 4.6 a 26.4 ± 4.4 a 29.1 ± 6.8 b < 0.001
§ among ever smokers. BMI body mass index. Results are expressed as number of participants and (column percentage) for categorical variables and as average ±
standard deviation or median [interquartile range] for continuous variables. Between-group analysis performed using chi-square test for categorical variables and
analysis of variance or nonparametric Kruskal-Wallis test (ǂ) for continuous variables. Post-hoc between-group comparisons of BMI performed using Scheff’s
method; values with differing superscripts are significantly different at p < 0.005. The group “chronic obstruction” also contains the subjects with both “chronic
obstruction and possible restriction”. The group “reversible obstruction” also contains the subject with both “reversible obstruction and possible restriction”
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multivariate analysis, second-hand tobacco exposure before
age 18 was associated with a protective effect for reversible
obstruction (RRR = 0.50). Ever-smokers had more often
experienced second-hand tobacco smoke exposure, both in
childhood (47.3% vs. 36.6%, p < 0.001) and especially in
adulthood (63.8% vs. 38.2%, p < 0.001).
With regard to other smokes and fumes, approximately
26% of men and 9% of women had been exposed (overall
16.6%), generally in relation to their professional environ-
ment (e.g. work as motor mechanics, professional cleaners,
factory or kitchen workers). Subjects exposed to other
smokes or fumes were more likely to have possible lung
restriction compared with the rest of the population (3.1%
vs. 1.6%, RRR = 1.87 in multivariate analysis), but were no
different with regard to obstruction. Ever-smokers had
more frequently been exposed to other smokes and fumes
than never-smokers (19.3% vs. 13.8%, p < 0.001).
BMI was significantly higher in the group with
possible restriction compared to the other groups.
Chronic airway obstruction was found in 1.5% of
never-smokers, representing 19% of all chronic obstruc-
tions. These subjects did not differ from smokers with
chronic obstruction with respect to mean age or gender
distribution. They were more likely to have a history of
asthma than smokers with chronic obstruction (36.0%
vs. 16.5%, p = 0.049) but had no difference in prevalence
of respiratory symptoms or other respiratory diagnoses.
Respiratory symptoms and their association with lung
function abnormalities
Questionnaire results for respiratory symptoms accord-
ing to spirometric categories are shown in Table 3. Less
than 5% of participants reported chronic respiratory
symptoms: cough; sputum production; or dyspnoea
rated mMRC ≥2. There was no gender difference in
symptoms except that women more often reported
slight dyspnoea on effort (mMRC =1) than men.
A considerable amount of subjects with chronic
cough, chronic sputum production and chronic
dyspnoea mMRC ≥2 had an abnormal spirometry
result (18.5, 29.3 and 28.6% respectively). In particular,
these participants showed more often chronic obstruc-
tion (14.3, 29.3 and 28.6% respectively). Conversely,
compared to the rest of the population, subjects with
chronic airway obstruction suffered more often from
chronic cough (14.8% vs. 4.0%, p < 0.001), sputum
production (13.3% vs. 2.0%, p < 0.001) and dyspnoea
mMRC ≥2 (5.5% vs 1.3%, p < 0.001); but only sputum
production stayed significantly increased after
multivariate analysis (p = 0.005, RRR 3.91). In multi-
variate analysis, subjects with possible lung restriction
were more often suffering from dyspnoea mMRC≥2
(p = 0.001, RRR 6.87).
The subjects defined as obstructive according to
the fixed ratio but not obstructive according to LLN
had a similar prevalence of chronic cough and spu-
tum production to that of non obstructive subjects.
Dyspnoea levels in these people were in between
those of normal subjects and obstructive subjects
according to LLN, but were not significantly differ-
ent from either group (Table 4).
Ever-smokers suffered more from chronic cough
(5.7% vs. 3.1%, p < 0.001) and chronic sputum
production (3.5% vs. 1.4%, p < 0.001) than never-
smokers, even though overall prevalence of
symptoms remained low. There was no difference
with regard to dyspnoea mMRC ≥2 (1.8% vs. 1.1%,
p = 0.122).
Higher BMI was associated with higher grade of
dyspnoea: 30.9 kg/m2 in participants with dyspnoea
mMRC ≥2 compared to 26.3 kg/m2 in participants
with dyspnoea mMRC ≤1 (p < 0.001).
History of respiratory diagnoses and their association
with lung function abnormalities
Questionnaire results for self-reported respiratory
diagnoses according to spirometric categories are
shown in Table 5. Approximately 7% of women and
4% of men (overall 5.6%) indicated a medical diagno-
sis of asthma (p = 0.003); 25.7% of those had an
Table 3 Respiratory symptoms according to spirometry results. PneumoLaus study, 2014–2017, Lausanne, Switzerland
Overall Normal spirometry Chronic obstruction Reversible obstruction Possible restriction p-value
N 3342 3070 128 83 61
Chronic cough 146 (4.4) 119 (3.9) 19 (14.8) 5 (6.0) 3 (4.9) < 0.001
Chronic sputum production 82 (2.5) 58 (1.9) 17 (13.3) 4 (4.8) 3 (4.9) < 0.001
Dyspnoea according to mMRC scale < 0.001
0 1730 (51.8) 1635 (53.3) 45 (35.2) 33 (39.8) 17 (27.9)
1 1563 (46.8) 1400 (45.6) 76 (59.4) 48 (57.8) 39 (63.9)
≥ 2 49 (1.5) 35 (1.1) 7 (5.5) 2 (2.4) 5 (8.2)
COPD chronic obstructive pulmonary disease, mMRC Modified Medical Research Council dyspnoea scale. Results are expressed as number of participants and
(column percentage). Between-group analysis performed using Fisher’s exact test. The group “chronic obstruction” also contains the subjects with both “chronic
obstruction and possible restriction”. The group “reversible obstruction” also contains the subject with both “reversible obstruction and possible restriction”
Lenoir et al. Respiratory Research          (2018) 19:250 Page 5 of 9
abnormal spirometry result, 21.9% had an obstruction.
There was no gender difference with regard to other
known respiratory diseases.
A medical diagnosis of chronic bronchitis, emphy-
sema or COPD was reported by 1.6% of participants,
and was more frequent amongst ever-smokers (2.7%
vs. 0.5%, p < 0.001). Whilst more than half of them
(54.7%) were normal according to their spirometry, a
significant number of these “normal” individuals had
chronic respiratory symptoms: 41.4% cough, 17.2%
sputum production and 6.9% dyspnoea mMRC ≥2.
There was no difference between smoking status cat-
egories with regards to history of asthma or other
pulmonary diseases.
Chronic obstruction was associated with a medical
diagnosis of asthma (RRR = 4.71) and chronic bron-
chitis, emphysema or COPD (RRR = 9.64) in multivari-
ate analysis (Table 6). Similarly, reversible obstruction
was associated with a diagnosis of asthma (RRR = 5.09)
but also with previous lung operation (RRR = 9.57).
Possible lung restriction was more prevalent in subjects
with a diagnosis of asthma (RRR = 2.72), previous lung
operation (RRR = 6.74) and any other pulmonary
disease (RRR = 7.84).
Only one third of subjects with chronic obstruction
(32.8%) had a history of either: 1) asthma; or 2) chronic
bronchitis, emphysema or COPD (6 participants had
both). In fact, among all chronic airway obstructions,
64.1% of subjects were not aware of any respiratory
disease at all. Whilst most of these people had no
respiratory symptoms, 9.8% had chronic cough, 7.3%
had chronic sputum production and 3.7% had dyspnoea
mMRC ≥2.
Discussion
The results of the PneumoLaus study reflect respiratory
function in a sample of a Swiss city’s general population.
Compared to similar studies, the prevalence of abnormal
lung function was low in our study. Roughly speaking,
we found 92% of subjects with normal spirometry, 6%
with airway obstruction and 2% with possible lung
restriction, with less than 1% showing a mixed ventila-
tory pattern. In the obstructive group, more than one
third was reversible after bronchodilation, a proportion
already observed in previous studies.
Comparison with previous population studies
Similar population studies have been reported, such as the
international Burden of Lung Disease (BOLD) Study [13],
the European Respiratory Society Spirometry Tent [14],
the Rotterdam Study in the Netherlands [15] or the Swiss
study on Air Pollution and Lung Diseases In Adults
(SAPALDIA) [16]. BOLD was a multicentre study,
assessing the prevalence of airway obstruction using the
NHANES III reference values [6], and employing bron-
chodilation with 200 μg salbutamol in all subjects. The
prevalence of chronic airway obstruction was
geographically heterogeneous, ranging from 5.7 to 23.0%
for men and from 1.8 to 20.7% for women, but overall
notably higher than the 3.9% found in our study. Similarly,
the prevalence of possible lung restriction was higher in
BOLD (8.4 to 67.7% in men, 8.4 to 68.7% in women) than
Table 4 Respiratory symptoms according to definition of obstruction. PneumoLaus study, 2014–2017, Lausanne, Switzerland
Group 1: FEV1/
FVC < LLN
Group 2: FEV1/FVC >
LLN but < 0.7
Group 3: FEV1/FVC >
LLN and > 0.7
p-value Group
1 vs. 2
p-value Group
2 vs. 3
p-value Group
1 vs. 3
N 188 (5.6) 224 (6.7) 2930 (87.7)
Chronic cough 21 (11.2) 11 (4.9) 113 (3.9) 0.018 0.428 < 0.001
Chronic sputum
production
18 (9.6) 7 (3.1) 56 (1.9) 0.006 0.208 < 0.001
Chronic dyspnoea
mMRC ≥2
8 (4.3) 5 (2.2) 36 (1.2) 0.241 0.199 0.001
Results are expressed as number of participants and (percentage) for categorical variables. Between-group analysis performed using chi-square test. mMRC
Modified Medical Research Council dyspnoea scale
Table 5 Self-reported respiratory diagnoses according to spirometry results. PneumoLaus study, 2014–2017, Lausanne, Switzerland
Overall Normal spirometry Chronic obstruction Reversible obstruction Possible restriction p-value
N 3342 3070 128 83 61
Asthma 187 (5.6) 139 (4.5) 26 (20.3) 15 (18.1) 7 (11.5) < 0.001
Chronic bronchitis, emphysema or COPD 53 (1.6) 29 (0.9) 22 (17.2) 2 (2.4) 0 (0) < 0.001 a
Any other pulmonary disease 40 (1.2) 27 (0.9) 4 (3.1) 2 (2.4) 7 (11.5) < 0.001 a
Previous lung operation 21 (0.6) 11 (0.4) 2 (1.6) 3 (3.6) 5 (8.2) < 0.001 a
COPD chronic obstructive pulmonary disease. Results are expressed as number of participants and (column percentage). Between-group analysis performed using
chi-square test or Fisher’s exact test (a).The group “chronic obstruction” also contains the subjects with both “chronic obstruction and possible restriction”. The
group “reversible obstruction” also contains the subject with both “reversible obstruction and possible restriction”
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in our study (2.2%). In the ERS spirometry tent study, spir-
ometry was performed in volunteers in six European cities
during ERS congresses from 2004 to 2009. No post-bron-
chodilation spirometry was performed. Overall prevalence
of obstruction was 12.4% as defined according to LLN de-
rived from population-specific prediction equations and
20.3% as defined by GOLD. In the Rotterdam study, ob-
struction was defined according to GOLD by a fixed ratio
FEV1/FVC < 0.70, and no reversibility test was performed.
The prevalence of obstruction was 4.7% at baseline and
13.6% in 2008 [17]. SAPALDIA is a multicentre study set
in eight different Swiss regions, representing
environmentally distinct conditions, investigating
long-term effects of low-to-moderate air pollution. In
the original study, bronchodilation was applied with
200 μg salbutamol if obstruction was found (FEV1/
FVC < 80% predicted or FEV1 < 70%), which was the
case of 4.7% of participants. In the first follow-up
study (SAPALDIA 2), no bronchodilation was applied,
and the investigators found 10.0% prevalence of
obstruction [18], more than the 6.3% before broncho-
dilation in our study. Reference values for SAPALDIA
2 were Swiss [19].
In search of an explanation for our low rate of abnormal
results, several factors have to be taken into account. In
our population, half of participants were former or current
smokers, less than in most other population studies. In
the SAPALDIA study, 64.2% participants were former or
current smokers at baseline [16], and this was the case of
63.4% participants in the Rotterdam Study [15]. The
proportion of ever-smokers was also higher in Hannover
(70.0%) and in Salzburg (59.4%), the closest BOLD sites to
Lausanne, with prevalence rates for chronic obstruction of
18.1 and 26.6% respectively [20]. It might therefore be that
the comparatively low rate of ever-smokers in Pneumo-
Laus partly explains the lower prevalence of chronic
obstruction. Nevertheless, the rate of ever-smokers in the
ERS spirometry tent study was very close to ours (48.8%)
but their rate of obstruction was still significantly higher.
Impact of current reference values and guidelines
As expected in a population of this age range, the
proportion of airway obstructions was lower using the
LLN than the 0.70 fixed ratio for FEV1/FVC. Although
the definition of airway obstruction by the LLN is
rational, it has been argued that the 0.70 fixed ratio
might detect subjects evolving towards obstruction but
not yet fulfilling the LLN criteria [21]. For this inter-
mediate group, obstructive according to the fixed ratio
but not according to the LLN, our results show that
these individuals behave like non-obstructive subjects
with regard to chronic cough and chronic sputum pro-
duction. Prevalence of dyspnoea mMRC ≥2 in this inter-
mediate group falls between the normal and obstructive
by LLN subjects with no significant difference from ei-
ther of them. Since the difference between normal
and obstructive by LLN subjects is significant (p =
0.001), this hints at a continuum between the three
groups, although this should be interpreted with cau-
tion given the small size of these subgroups.
Table 6 Multivariable analysis of the associations between clinical variables and spirometry results, Pneumolaus study, 2014-
2017, Lausanne, Switzerland
Chronic obstruction p-value Reversible obstruction p-value Possible restriction p-value
Age (per year) 1.009 (0.989–1.028) 0.383 0.986 (0.964–1.009) 0.236 0.997 (0.971–1.024) 0.852
Gender (ref = woman) 1.589 (1.074–2.350) 0.02 1.187 (0.751–1.877) 0.463 1.796 (1.037–3.112) 0.037
Smoking status (ref = never) 3.495 (2.185–5.589) < 0.001 2.734 (1.654–4.519) < 0.001 0.534 (0.300–0.951) 0.033
Second-hand tobacco (ref = no)
Before age 18 0.693 (0.467–1.028) 0.068 0.496 (0.305–0.806) 0.005 1.169 (0.679–2.014) 0.573
As an adult 1.496 (0.991–2.259) 0.055 1.142 (0.717–1.818) 0.575 0.618 (0.349–1.092) 0.097
Other smoke / fumes (ref = no) 0.799 (0.484–1.320) 0.382 0.750 (0.399–1.409) 0.371 1.874 (1.012–3.470) 0.046
Chronic cough (ref = no) 0.822 (0.333–2.025) 0.670 0.637 (0.175–2.324) 0.495 0.558 (0.100–3.104) 0.505
Chronic sputum production (ref = no) 3.907 (1.524–10.01) 0.005 2.392 (0.578–9.895) 0.229 1.846 (0.303–11.25) 0.506
Dyspnoea (ref = MRC < 2) 1.869 (0.665–5.250) 0.235 1.435 (0.319–6.467) 0.638 6.868 (2.309–20.43) 0.001
Self-reported diagnosis of (ref = no)
Asthma 4.709 (2.745–8.077) < 0.001 5.09 (2.760–9.386) < 0.001 2.719 (1.172–6.308) 0.020
Chronic bronchitis, emphysema or COPD 9.637 (4.801–19.35) < 0.001 1.876 (0.413–8.523) 0.415 NA
Any other pulmonary disease 1.479 (0.385–5.688) 0.569 1.193 (0.207–6.872) 0.843 7.844 (2.597–23.70) < 0.001
Previous lung operation (ref = no) 2.409 (0.425–13.67) 0.321 9.572 (2.046–44.78) 0.004 6.738 (1.682–26.99) 0.007
NA not assessable. Results are expressed as relative risk ratio and (95% confidence interval) using normal spirometry as the reference. The group “chronic
obstruction” also contains the subjects with both “chronic obstruction and possible restriction”. The group “reversible obstruction” also contains the subject with
both “reversible obstruction and possible restriction”
Lenoir et al. Respiratory Research          (2018) 19:250 Page 7 of 9
We followed the ATS/ERS recommendation for bron-
chodilation and used a dose of salbutamol twice as high
as in the BOLD study, which may further contribute to a
lower prevalence of chronic obstruction. Finally, in
contrast to the above-mentioned studies, we used the
Global Lung Function Initiative (GLI) 2012 reference
values. Nevertheless, these are very similar to NHANES
III reference values used by BOLD and to the Swiss
reference values used by SAPALDIA. If anything, the use
of GLI 2012 should result in a higher prevalence of
obstruction due to a slightly higher LLN [7, 22]. The
hypothesis that a particular characteristic of our popula-
tion is responsible for these differences is supported by
the fact that a recent study in Northern Italy also found
a higher prevalence of chronic obstruction than ours
(9.1%), despite a population sample with comparable
smoking habits (ever-smokers 46%) and a very similar
methodology to our own: use of GLI 2012 reference
values and bronchodilation with 400 μg salbutamol if
FEV1/FVC was lower than the LLN [23].
Participant characteristics
We found more abnormal spirometry results in men than
in women but this difference disappeared when analysis
was applied to ever-smokers only, even though women
are suspected to be at greater risk of smoking-induced
lung function impairment [24]. This points to the poten-
tial role of other factors contributing to the development
of chronic lung diseases [25]. Indeed, occupational expos-
ure to dust, fumes and smoke was considerably higher in
men in our population (26% vs. 9% in women). In terms
of spirometry, subjects with occupational exposure more
often had possible lung restriction.
BMI was higher in participants with possible lung
restriction. This reflects similar results in European and
Swiss cohorts [26] even though the exact relationship
between obesity and the restrictive spirometric pattern is
complex, and only a minority of obese subjects effect-
ively display this pattern [27].
Only one third of our participants displaying chronic
airway obstruction were aware of a respiratory disease.
This observation highlights the well-known problem of
COPD underdiagnosis [28, 29]. On the other hand, more
than half of the subjects who reported a diagnosis of
COPD, chronic bronchitis or emphysema had normal
spirometry results, pointing either to COPD misdiagnosis,
or to the possibility that diagnosis was mainly driven by
respiratory symptoms [30].
Strengths and limitations
The main limitation of our study consists of our popula-
tion sample being part of the second follow-up of a
cohort study. This implies a possible selection bias of
particularly motivated and health-interested participants
and might reflect in the relatively low proportion of
ever-smokers [31, 32]. The cross-sectional design of the
study limits the questions which can be addressed in this
paper but should not strictly affect the quality of the
data or the main results.
The main strengths of the PneumoLaus study are the
use of the GLI 2012 reference equations, allowing to
optimally adjust spirometry results for age and ethnicity
as well as height and gender; the strict application of
ATS/ERS criteria for bronchodilation, using a full salbu-
tamol dose and therefore permitting to correctly classify
obstruction into chronic and reversible; and the
performance of all spirometries by one single laboratory
technician, avoiding inter-observer variability.
Conclusion
This study shows an unusually low rate of abnormal
spirometry results in the general population of Lausanne,
a medium-sized Swiss city, using GLI 2012 reference
values. This is not explained by differences in design or
methods when compared to similar population studies,
but seems to be an inherent characteristic of our
population.
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